Preponderance of


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2019
Historique:
received: 14 03 2019
accepted: 20 06 2019
entrez: 10 8 2019
pubmed: 10 8 2019
medline: 11 11 2020
Statut: epublish

Résumé

One of the primary targets of immune checkpoint inhibition is the negative immune regulatory molecule CTLA-4. Immune-related adverse events are commonly observed following CTLA-4 inhibition in melanoma treatment, and a spectrum of these conditions are also observed in individuals with germline haploinsufficiency of

Identifiants

pubmed: 31396201
doi: 10.3389/fimmu.2019.01544
pmc: PMC6664875
doi:

Substances chimiques

Antirheumatic Agents 0
CTLA-4 Antigen 0
CTLA4 protein, human 0
Abatacept 7D0YB67S97

Types de publication

Case Reports Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1544

Références

Nature. 2001 Mar 29;410(6828):604-8
pubmed: 11279501
Nature. 2001 Mar 29;410(6828):608-11
pubmed: 11279502
J Comput Chem. 2004 Oct;25(13):1605-12
pubmed: 15264254
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Science. 2014 Sep 26;345(6204):1623-1627
pubmed: 25213377
Nat Med. 2014 Dec;20(12):1410-1416
pubmed: 25329329
J Allergy Clin Immunol. 2016 Jan;137(1):327-330
pubmed: 26478010
N Engl J Med. 2016 Sep 1;375(9):819-29
pubmed: 27433843
Eur J Hum Genet. 2017 Jun;25(6):711-718
pubmed: 28272538
Proc Natl Acad Sci U S A. 2017 May 23;114(21):E4223-E4232
pubmed: 28484017
Clin Genet. 2018 Mar;93(3):647-655
pubmed: 29077208
J Clin Immunol. 2018 Jan;38(1):96-128
pubmed: 29226302
Front Immunol. 2017 Dec 15;8:1824
pubmed: 29375547
J Allergy Clin Immunol. 2018 Dec;142(6):1932-1946
pubmed: 29729943
Front Immunol. 2018 Sep 10;9:2012
pubmed: 30250467
Science. 1995 Nov 10;270(5238):985-8
pubmed: 7481803
Immunity. 1995 Nov;3(5):541-7
pubmed: 7584144
J Exp Med. 1994 Dec 1;180(6):2049-58
pubmed: 7964482
J Immunol. 1996 Feb 1;156(3):1047-54
pubmed: 8557978
Science. 1996 Mar 22;271(5256):1734-6
pubmed: 8596936

Auteurs

Owen M Siggs (OM)

Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.
Department of Ophthalmology, Flinders University, Adelaide, SA, Australia.

Amanda Russell (A)

Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.

Davinder Singh-Grewal (D)

The Children's Hospitals Network, The University of New South Wales, Sydney, NSW, Australia.

Melanie Wong (M)

The Children's Hospitals Network, The University of New South Wales, Sydney, NSW, Australia.

Pearl Chan (P)

The Children's Hospitals Network, The University of New South Wales, Sydney, NSW, Australia.

Maria E Craig (ME)

The Children's Hospitals Network, The University of New South Wales, Sydney, NSW, Australia.

Ted O'Loughlin (T)

The Children's Hospitals Network, The University of New South Wales, Sydney, NSW, Australia.

Michael Stormon (M)

The Children's Hospitals Network, The University of New South Wales, Sydney, NSW, Australia.

Christopher C Goodnow (CC)

Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.
St. Vincent's Clinical School, The University of New South Wales, Sydney, NSW, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH